EC chemotherapy

DRUG3 trials

Sponsors

PhytoHealth Corporation, Shanghai Jiao Tong University School of Medicine

Conditions

Breast CancerBreast Cancer InvasiveCancer-related FatigueNeutropenia, Malignant

Phase 2

PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

CompletedNCT03314805

PhytoHealth CorporationCancer-related Fatigue, Neutropenia, Malignant

Start: 2018-03-01End: 2021-08-27Updated: 2025-06-04

Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

TerminatedNCT04066790

Shanghai Jiao Tong University School of MedicineBreast Cancer

Start: 2019-09-09End: 2020-04-30Updated: 2020-05-19

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Active, not recruitingNCT04398914

Shanghai Jiao Tong University School of MedicineBreast Cancer Invasive

Start: 2020-05-30End: 2027-12-30Target: 216Updated: 2022-03-31

Related Papers

Astragalus polysaccharides improve adjuvant chemotherapy-induced fatigue for patients with early breast cancer.

2024-10-2812 citations

Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study.

Journal of Clinical Oncology2024-06-01

Effect of astragalus polysaccharides (PG2) treatment of adjuvant chemotherapy-induced fatigue in premenopausal patients with breast cancer.

Journal of Clinical Oncology2023-06-012 citations